Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
1.780
-0.015 (-0.84%)
At close: Aug 13, 2025, 4:00 PM
1.790
+0.010 (0.56%)
After-hours: Aug 13, 2025, 7:05 PM EDT
Humacyte Employees
As of December 31, 2024, Humacyte had 220 total employees, including 218 full-time and 2 part-time employees. The number of employees increased by 35 or 18.92% compared to the previous year.
Employees
220
Change (1Y)
35
Growth (1Y)
18.92%
Revenue / Employee
$3,718
Profits / Employee
-$266,945
Market Cap
281.90M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 220 | 35 | 18.92% |
Dec 31, 2023 | 185 | 21 | 12.80% |
Dec 31, 2022 | 164 | 18 | 12.33% |
Dec 31, 2021 | 146 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
HUMA News
- 1 day ago - Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Progress - Seeking Alpha
- 2 days ago - Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 days ago - Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025 - GlobeNewsWire
- 21 days ago - Humacyte Announces First Symvess™ Sale to Military Treatment Facility - GlobeNewsWire
- 5 weeks ago - Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency - GlobeNewsWire
- 2 months ago - Humacyte: Revenue Ramp From Symvess Incoming - Seeking Alpha
- 2 months ago - Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting - GlobeNewsWire